Philippe Ravaud

Research interests

Publications

• CONSORT 2025 statement: updated guideline for reporting randomised trials

  BMJ · 2025 · 10.1136/bmj-2024-081123

• Efficacy and safety of COVID-19 vaccines

  Cochrane Database of Systematic Reviews · 2022 · https://doi.org/10.1002/14651858.cd015477

• Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

  The Lancet Respiratory Medicine · 2021 · https://doi.org/10.1016/s2213-2600(20)30556-7

• Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

  BMJ · 2020 · https://doi.org/10.1136/bmj.m1844

• Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

  JAMA Internal Medicine · 2020 · https://doi.org/10.1001/jamainternmed.2020.6820

• Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

  Annals of the Rheumatic Diseases · 2018 · https://doi.org/10.1136/annrheumdis-2017-212878

• Living systematic reviews: 4. Living guideline recommendations

  Journal of Clinical Epidemiology · 2017 · https://doi.org/10.1016/j.jclinepi.2017.08.009

• Living systematic review: 1. Introduction—the why, what, when, and how

  Journal of Clinical Epidemiology · 2017 · https://doi.org/10.1016/j.jclinepi.2017.08.010

• Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

  The Lancet Infectious Diseases · 2017 · https://doi.org/10.1016/s1473-3099(16)30521-7

• CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts

  Annals of Internal Medicine · 2017 · https://doi.org/10.7326/m17-0046

• Living systematic reviews: 2. Combining human and machine effort

  Journal of Clinical Epidemiology · 2017 · https://doi.org/10.1016/j.jclinepi.2017.08.011

• EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide

  RMD Open · 2015 · https://doi.org/10.1136/rmdopen-2014-000022

• Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1404231

• Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome

  JAMA · 2014 · https://doi.org/10.1001/jama.2014.7682

• Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

  Annals of the Rheumatic Diseases · 2014 · https://doi.org/10.1136/annrheumdis-2014-206008

• Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)

  Annals of the Rheumatic Diseases · 2014 · https://doi.org/10.1136/annrheumdis-2013-204615

• Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study

  Annals of the Rheumatic Diseases · 2013 · https://doi.org/10.1136/annrheumdis-2013-203991

• Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study

  Arthritis Care & Research · 2012 · https://doi.org/10.1002/acr.21747

• EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome

  Annals of the Rheumatic Diseases · 2011 · https://doi.org/10.1136/ard.2010.143743

• Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

  Arthritis & Rheumatism · 2010 · https://doi.org/10.1002/art.27541

• Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

  Arthritis & Rheumatism · 2010 · https://doi.org/10.1002/art.27555

• EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome

  Annals of the Rheumatic Diseases · 2009 · https://doi.org/10.1136/ard.2009.110619

• Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration

  Annals of Internal Medicine · 2008 · https://doi.org/10.7326/0003-4819-148-4-200802190-00008

• What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?

  European Heart Journal · 2007 · https://doi.org/10.1093/eurheartj/ehm001

• Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?

  European Heart Journal · 2005 · https://doi.org/10.1093/eurheartj/ehi471

• High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.03.0551

• High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial

  Blood · 1998 · https://doi.org/10.1182/blood.v92.9.3131

Current projects

No projects listed.